Oracle vs. IBM: Which Cloud Computing Stock Is the Better Buy?

Oracle shares have fallen ~40% over the past year as investors question whether OpenAI can fund Oracle’s $638B remaining performance obligations starting in 2027; the key OpenAI-linked contract is worth $300B+ over five years. On fundamentals, Oracle’s Oracle Cloud revenue rose 47% YoY in fiscal 2026 Q4, while IBM’s hybrid cloud revenue grew 13% YoY in Q1 and IBM Z revenue is up 51% YoY, though IBM Z remains a small part of total revenue. Valuations are similar (Oracle ~25x P/E vs IBM ~26x), but the article argues Oracle is growing faster—despite the backlog-payment risk tied to OpenAI.

Analysis

ORCL’s equity risk is no longer primarily about cloud adoption; it is about revenue quality and funding certainty. When a single counterparty dominates forward bookings, the multiple becomes hostage to financing markets, and any slippage in 2027 payment expectations can compress the stock before it ever hits the revenue line. The second-order loser is the AI infrastructure trade broadly: if OCI backlog credibility cracks, investors will re-underwrite all “hypergrowth” cloud names on cash collection, not just bookings.

IBM’s setup is the opposite: less upside beta, but lower fragility. The mainframe/AI inference angle can keep driving high-margin attach rates in software and services, yet the equity impact is limited unless IBM can translate that into sustained acceleration in the much larger hybrid cloud stack. In other words, IBM can win a few quarters of multiple stability, but it probably does not deserve a structural re-rate unless cloud growth re-accelerates above low-teens and services margin expands.

The contrarian miss is that the market may be overfocused on ORCL’s headline growth and underfocused on the gap between backlog and monetization. That gap matters most over the next 6-18 months, as rates, customer funding, and AI capex discipline will determine whether backlog converts cleanly or gets repriced. Falsifiers: a clean quarter showing broad-based OCI growth without further customer concentration, or an OpenAI funding solution that materially de-risks 2027 cash flows; conversely, any guidance haircut or backlog commentary implying slower conversion should hit ORCL first.

Key Decisions for Investors

• Short ORCL on strength into earnings/guidance windows; thesis is multiple compression from customer-concentration risk, with downside greatest if backlog commentary keeps pointing to 2027 funding uncertainty.
• Pair trade: long IBM / short ORCL for a 1-3 month relative-value expression. IBM has less narrative risk and should hold up better if the market rotates from growth-quality to cash-flow quality.
• If you want convexity, buy ORCL puts 3-6 months out rather than outright shorting; the key catalyst is not near-term revenue, it is any deterioration in backlog credibility or financing commentary.
• Watch IBM as a tactical long only on evidence of sustained mainframe-driven software uplift; without broader hybrid-cloud acceleration, treat it as a defensive compounder, not a breakout AI winner.
• Set a hard stop on the ORCL short if OCI growth re-accelerates while forward bookings diversify away from the largest customer; that would invalidate the concentration-risk thesis.